[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609077":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":55,"collaborators":20,"id":57,"slug":20,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-P16-093 PET\u002FCT","EXPERIMENTAL","Intravenous injection of 68Ga-P16-093 with a dosage of 111-148 MBq (3-4 mCi), followed by PET\u002FCT or PET\u002FMRI acquisition according to standard methods.",[13],"Drug: 68Ga-P16-093",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","68Ga-P16-093","Intravenous injection of Ga-P16-093 with a dosage of 111-148 MBq (3-4 mCi), followed by PET\u002FCT or PET\u002FMRI acquisition according to standard methods.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Weibing Miao, MD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","86-0591-87981618","miaoweibing@126.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Guochang Wang, MD","86-0591-87981619","guochang1007@163.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":44,"coordinates":45},"Point",[46,47],119.30611,26.06139,{"lat":47,"lon":46},[50,52,54],{"name":23,"role":27,"phone":51,"phoneExt":20,"email":29},"+86-0591 87981618",{"name":31,"role":27,"phone":53,"phoneExt":20,"email":33},"+86-0591-87981619",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":56,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100609077",false,"NCT07209865","68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI","68Ga-P16-093 PET Imaging in the Diagnostic Study of Newly Diagnosed, Untreated Prostate Cancer, With a Head-to-head Comparison to mpMRI","Inclusion Criteria:\n\n* Biopsy-confirmed adenocarcinoma of the prostate.\n* No anti-tumor treatment received prior to the PET imaging.\n* Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.\n* Radical prostatectomy scheduled within 28 days after PET imaging.\n\nExclusion Criteria:\n\n* Patients with other malignant tumors\n* Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.","MALE","18 Years","80 Years",{"count":67,"type":68},50,"ESTIMATED","INTERVENTIONAL",[71,72],"PHASE1","PHASE2","68Ga-P16-093 is a novel radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-P16-093 PET imaging (PET\u002FCT or PET\u002FMRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).",[75],"Prostate Cancer (Adenocarcinoma)",[77,78,79,80],"PSMA","Prostate cancer","PET imaging","mpMRI","2025-09-30",{"date":83,"type":84},"2025-10-07","ACTUAL",{"date":86,"type":84},"2024-10-01",{"date":88,"type":68},"2026-06-30",{"name":5,"class":6},1]